KX 01

Drug Profile

KX 01

Alternative Names: KX-01; KX-2391

Latest Information Update: 14 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Kinex Pharmaceuticals
  • Developer Athenex; Hanmi Pharmaceutical; Kinex Pharmaceuticals; PharmaEssentia Corporation
  • Class Acetamides; Antineoplastics; Morpholines; Pyridines; Skin disorder therapies; Small molecules
  • Mechanism of Action Angiogenesis inhibitors; Caspase stimulants; Interleukin 2 inhibitors; Keratinocyte inhibitors; Proto-oncogene protein c-bcl-2 inhibitors; Src-Family kinase inhibitors; Tubulin polymerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Psoriasis
  • Phase I/II Solid tumours
  • Phase I Actinic keratosis; Acute myeloid leukaemia
  • No development reported Prostate cancer

Most Recent Events

  • 02 Jun 2017 Adverse events data from a phase Ib trial in Acute myeloid leukaemia presented at the 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO-2017)
  • 27 Jan 2017 Athenex reacquires the right to market and commercialise KX 01 for Actinic keratosis in China
  • 27 Jan 2017 PharmaEssentia maintains the rights to develop and commercialise KX 01 for Actinic keratosis in Taiwan and for Psoriasis in Taiwan and China
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top